Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
P-glycoprotein, an ATP-driven drug efflux pump, is a major obstacle to the delivery of small-molecule drugs across the blood-brain barrier and into the CNS. Here we test a unique signaling-based strategy to overcome this obstacle. We used a confocal microscopy-based assay with isolated rat brain capillaries to map a signaling pathway that within minutes abolishes P-glycoprotein transport activity without altering transporter protein expression or tight junction permeability. This pathway encompasses elements of proinflammatory- (TNF-α) and sphingolipid-based signaling. Critical to this pathway was signaling through sphingosine-1-phosphate receptor 1 (S1PR1). In brain capillaries, S1P acted through S1PR1 to rapidly and reversibly reduce P-glycoprotein transport activity. Sphingosine reduced transport by a sphingosine kinase-dependent mechanism. Importantly, fingolimod (FTY720), a S1P analog recently approved for treatment of multiple sclerosis, also rapidly reduced P-glycoprotein activity; similar effects were found with the active, phosphorylated metabolite (FTY720P). We validated these findings in vivo using in situ brain perfusion in rats. Administration of S1P, FTY720, or FTY729P increased brain uptake of three radiolabeled P-glycoprotein substrates, 3 H-verapamil (threefold increase), 3 H-loperamide (fivefold increase), and 3 H-paclitaxel (fivefold increase); blocking S1PR1 abolished this effect. Tight junctional permeability, measured as brain 14 C-sucrose accumulation, was not altered. Therefore, targeting signaling through S1PR1 at the blood-brain barrier with the sphingolipid-based drugs, FTY720 or FTY720P, can rapidly and reversibly reduce basal P-glycoprotein activity and thus improve delivery of small-molecule therapeutics to the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
The outs and the ins of sphingosine-1-phosphate in immunity
Spiegel, S., & Milstien, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2974 · Cited by 810
Role of ABCC1 in export of sphingosine-1-phosphate from mast cells
Mitra, P., Oskeritzian, C. A., Payne, S. G., Beaven, M. A., Milstien, S., & Spiegel, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603734103 · Cited by 407 · cited 1×
“Previous experiments suggest that one or more Mrps can mediate S1P efflux from cells (19, 20).”
BackgroundBauer, B., Hartz, A. M. S., & Miller, D. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029512 · Cited by 275
Self-citationA Genomic Comparison of in vivo and in vitro Brain Microvascular Endothelial Cells
Calabria, A. R., & Shusta, E. V. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600518 · Cited by 109 · cited 1×
“We suspect that these differences reflect changes in cell physiology that occurred when the endothelial cells were isolated and developed into a continuous line (33).”
Background
Cited by
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
“…a steady state solute concentration in the lumen increases with increasing kpgp/km. Results from experiments reported in the literature show a time to reach steady state of 30–60 min (Hartz et al., 2004; Bauer et al., 2007; Hawkins et al., 2010; Cannon et al., 2012), consistent with kpgp/km ≈ 5.”
MethodSphingosine 1-phosphate: Lipid signaling in pathology and therapy
Cartier, A., & Hla, T. (2019) · Science · doi:10.1126/science.aar5551 · Cited by 613
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“When sphingosine-1-phosphate or fingolimod was coadministered, an increase in the brain uptake of radiolabeled verapamil, paclitaxel, and loperamide occurred [59].”
BackgroundImmune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
Metadata
- Authors
- Cannon, R. E., Peart, J. C., Hawkins, B. T., Campos, C. R., & Miller, D. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-09-04
- Volume
- 109
- Issue
- 39
- Pages
- 15930-15935
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2017665309
- Cited by
- 141
- References
- 5
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. https://app.cochat.ai/papers/10.1073/pnas.1203534109
- The paper
- Cannon, R. E., Peart, J. C., Hawkins, B. T., Campos, C. R., & Miller, D. S. (2012). Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1203534109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.